The risk of recurrence of ATIL has been reported to be 69% when using the same anti-TNFα agent again and 29% when another anti-TNF therapy is started.7 We therefore stopped infliximab therapy in the patient and initiated therapy with the IL-12/IL-23 inhibitor ustekinumab, which successfully maintained remission of the patient’s Crohn’s disease. The gene discussed is TNF; the disease is Crohn disease.